Service de médecine interne 2, Centre national de référence des lupus et syndrome des antiphospholipides, Hôpital de la Pitié-Salpêtrière, Paris, Inserm UMR-S 945, Paris, UPMC Université Paris 06, Paris
- Key words: autoimmunity, antiphospholipid syndrome, systemic lupus erythematosus, epilepsy
- DOI : 10.1684/epi.2010.0345
- Page(s) : 288-93
- Published in: 2010
Systemic lupus eythematosus (SLE) is an autoimmune disease characterized by varied clinical signs and the presence of antibodies directed towards the nuclear antigens. Identification of the antiphospolipid syndrome either occurring in the context of an autoimmune disease such SLE (secondary antiphospholipid syndrome) either without any identified disease (primary antiphospholipid syndrome) has received large attention showing that antiphospholipid antibodies (aPL) cause vascular thrombosis with the risk of diverse neurological complications such as convulsions/epilepsy. Recently it has been proposed that aPL could be potentially pathogenic for the neural tissue through the inhibition of the GABA-receptors, indirectly suggesting their role in the pathogenesis of epilepsy.